Depending upon different cyclopropylamines, several adducts were observed.[16, 17] Recently, we synthesized several known potent cyclopropylamine containing LSD1 inhibitors (e.g., compound 1), which were tested for their activity against a panel of leukemia and solid tumors, showing potent in vitro and in vivo activity against several AML cell lines.[13] Given these promising antileukemia activity, more structure activity relationship (SAR) studies of LSD1 inhibitors are therefore needed. This evidence concerns the gene KDM1A and leukemia.